The metabolism of alkylating agents is accompanied by the generation of reactive oxygen species. The aim of this study was to
treat estrogen receptor-positive and estrogen receptor-negative human breast cancer cells, MCF-7 and MDA-MB-231, respectively, with
cisplatin and five different berenil-platinum (II) complexes, and then to investigate the oxidative modifications of DNA, lipid and protein,
and to compare them with the profile of various pro- and antiapoptotic proteins. Changes in the levels of 8-hydroxy-2’-deoxyguanosine,
4-hydroxynonenal, carbonyl groups, dityrosine, active caspases 3, 8 and 9, as well as the expression of Bcl-2, Bax, cytochrome c, and
p53 were subsequently examined. Activities of superoxide dismutase, catalase and glutathione, vitamin C levels were also investigated.
Cellular reactions to cisplatin and the berenil-platinum (II) derivatives were more pronounced in MCF-7 cells as compared with the
MDA-MB231 cells. Furthermore, the berenil-platinum (II) derivatives were found to be more effective than cisplatin. All of the
complexes reduced the activity of superoxide dismutase and catalase, and also lowered the levels of non-enzymatic antioxidants.
Increased level of lipid, protein as well as DNA damage markers was also observed after berenil-platinum (II) derivatives treatment.
Similarly, the increase in the levels of the proapoptotic factors, were detected in MCF-7 and MDA-MB231 cells. Incubation of examined
cells with the berenil-platinum (II) complexes also led to the increase in the levels of active caspases 3, 8 and 9. In conclusion, the results
of the present study demonstrated that berenil-platinum (II) complexes more efficiently mediate cellular oxidative modifications and
proapoptotic metabolism, particularly in MCF-7 cells, compared to cisplatin. Pt2(isopropylamine)4berenil2 and Pt2(piperidine)4(berenil)2
notably affected the cellular metabolism of estrogen-positive breast cancer cells. Thus, these complexes may be valuable for the design of
additional anticancer drugs.